Literature DB >> 25409952

Atrial fibrillation: state of the art.

Matthias Hasun1, Eduard Gatterer, Franz Weidinger.   

Abstract

Atrial fibrillation (AF) is by far the most frequent heart rhythm disorder and is associated with a significantly increased risk of stroke, heart failure and death. Despite improvements in prevention and treatment, the prognosis has not changed significantly. To use new and promising pharmacological and interventional concepts for thromboembolic prophylaxis and treatment of AF, as well as prevention of recurrence, patient compliance has to be improved, physicians have to be trained and experience hast to be gained. A consistently carried 'anticoagulation pass' might be a promising piece of the puzzle.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25409952     DOI: 10.1007/s00508-014-0667-5

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  67 in total

1.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

Authors:  F D R Hobbs; D A Fitzmaurice; J Mant; E Murray; S Jowett; S Bryan; J Raftery; M Davies; G Lip
Journal:  Health Technol Assess       Date:  2005-10       Impact factor: 4.014

2.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

3.  Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference.

Authors:  Paulus Kirchhof; Gregory Y H Lip; Isabelle C Van Gelder; Jeroen Bax; Elaine Hylek; Stefan Kääb; Ulrich Schotten; Karl Wegscheider; Giuseppe Boriani; Michael Ezekowitz; Hans Diener; Hein Heidbuchel; Deirdre Lane; Luis Mont; Stephan Willems; Paul Dorian; Panos Vardas; Günter Breithardt; A John Camm
Journal:  Thromb Haemost       Date:  2011-11-02       Impact factor: 5.249

4.  ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT).

Authors:  Stefan H Hohnloser; Alessandro Capucci; Eric Fain; Michael R Gold; Isabelle C van Gelder; Jeff Healey; Carsten W Israel; Chu P Lau; Carlos Morillo; Stuart J Connolly
Journal:  Am Heart J       Date:  2006-09       Impact factor: 4.749

5.  Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation.

Authors:  D Kaireviciute; G Y H Lip; B Balakrishnan; G Uzdavinys; G Norkunas; G Kalinauskas; V Sirvydis; A Aidietis; U Zanetto; H Sihota; M Maheshwari; A D Blann
Journal:  J Thromb Haemost       Date:  2011-12       Impact factor: 5.824

6.  Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique.

Authors:  Feifan Ouyang; Matthias Antz; Sabine Ernst; Hitoshi Hachiya; Hercules Mavrakis; Florian T Deger; Anselm Schaumann; Julian Chun; Peter Falk; Detlef Hennig; Xingpeng Liu; Dietmar Bänsch; Karl-Heinz Kuck
Journal:  Circulation       Date:  2004-12-27       Impact factor: 29.690

Review 7.  Prediction of the atrial flutter circuit location from the surface electrocardiogram.

Authors:  Caroline Medi; Jonathan M Kalman
Journal:  Europace       Date:  2008-05-02       Impact factor: 5.214

8.  The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Authors:  Stuart J Connolly; Lars Wallentin; Michael D Ezekowitz; John Eikelboom; Jonas Oldgren; Paul A Reilly; Martina Brueckmann; Janice Pogue; Marco Alings; John V Amerena; Alvaro Avezum; Iris Baumgartner; Andrzej J Budaj; Jyh-Hong Chen; Antonio L Dans; Harald Darius; Giuseppe Di Pasquale; Jorge Ferreira; Greg C Flaker; Marcus D Flather; Maria Grazia Franzosi; Sergey P Golitsyn; David A Halon; Hein Heidbuchel; Stefan H Hohnloser; Kurt Huber; Petr Jansky; Gabriel Kamensky; Matyas Keltai; Sung Soon Kim; Chu-Pak Lau; Jean-Yves Le Heuzey; Basil S Lewis; Lisheng Liu; John Nanas; Razali Omar; Prem Pais; Knud E Pedersen; Leopoldo S Piegas; Dimitar Raev; Pal J Smith; Mario Talajic; Ru San Tan; Supachai Tanomsup; Lauri Toivonen; Dragos Vinereanu; Denis Xavier; Jun Zhu; Susan Q Wang; Christine O Duffy; Ellison Themeles; Salim Yusuf
Journal:  Circulation       Date:  2013-06-14       Impact factor: 29.690

9.  Acute termination of human atrial fibrillation by identification and catheter ablation of localized rotors and sources: first multicenter experience of focal impulse and rotor modulation (FIRM) ablation.

Authors:  Kalyanam Shivkumar; Kenneth A Ellenbogen; John D Hummel; John M Miller; Jonathan S Steinberg
Journal:  J Cardiovasc Electrophysiol       Date:  2012-11-06

10.  Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.

Authors:  A Weltermann; M Brodmann; H Domanovits; B Eber; M Gottsauner-Wolf; W M Halbmayer; J M Hiesmayr; P A Kyrle; F Längle; F X Roithinger; H Watzke; R Windhager; C Wolf; R Zweiker
Journal:  Wien Klin Wochenschr       Date:  2012-05-11       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.